Developing a new treatment using rhenium nanoliposomes for glioblastoma
Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma
This study is testing a new way to treat glioblastoma, a tough brain tumor, by using tiny particles to deliver medicine right to the tumor while protecting healthy brain tissue, and it's currently being tried out in animal models to see how safe and effective it is.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10687851 on NIH RePORTER |
What this research studies
This research focuses on creating a novel treatment for glioblastoma, the most aggressive type of brain tumor in adults. It involves using rhenium nanoliposomes to deliver therapeutic radionuclides directly to the tumor, minimizing damage to surrounding healthy brain tissue. The study has successfully developed a method to efficiently load these liposomes with the necessary radioisotopes, allowing for targeted therapy. By infusing these nanoliposomes directly into glioblastoma tumors in animal models, researchers are assessing their safety and effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with other types of brain tumors or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with glioblastoma by allowing for higher doses of radiation to be delivered directly to the tumor with reduced side effects.
How similar studies have performed: Previous research has shown promise in using targeted radionuclide therapies for brain tumors, indicating potential success for this novel approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Brenner, Andrew Jacob — University of Texas Hlth Science Center
- Study coordinator: Brenner, Andrew Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.